Previous 10 | Next 10 |
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) fell 4.3% to $0.707999 on volume of 163,563,003 shares PROSHARES TRUST (SQQQ) rose 2.9% to $11.9857 on volume of 127,669,453 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 5.2% to $4.62 on vol...
WILMETTE, Ill., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced it has received Human Research Ethics Committee (HREC) clearance in Australia to ...
2023-11-09 13:22:14 ET More on Monopar Therapeutics Seeking Alpha’s Quant Rating on Monopar Therapeutics Historical earnings data for Monopar Therapeutics Financial information for Monopar Therapeutics For further details see: Monopar Therapeutics ...
WILMETTE, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced third quarter 2023 financial results and summarized...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Monopar Therapeutics Inc. (MNPR) is expected to report $-0.19 for Q3 2023
2023-11-01 12:08:13 ET DENVER, Colo., Nov. 1, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; Aldeyra Therapeutics Inc (NASDAQ: ALDX), Cellectis SA (NASDAQ: CLLS), TG Therapeutics, Inc. (NASDAQ: TG...
2023-11-01 09:58:41 ET DENVER, Colo., Nov. 1, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Cellectis SA (NASDAQ: CLLS), TG Therapeutics, Inc. (NASDAQ: TGTX), Monopar Therapeutics Inc. (NASDAQ: MNPR), A...
2023-11-01 09:18:55 ET DENVER, Colo., Nov 1, 2023 ( www.247marketnews.com )- Monopar Therapeutics Inc (NASDAQ: MNPR) stated, this morning, that it’s presenting data, from its ongoing Phase 1b open-label, dose-escalating clinical trial of camsirubicin in patients with advanced sof...
WILMETTE, Ill., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will present data from its ongoing...
News, Short Squeeze, Breakout and More Instantly...
Monopar Therapeutics Inc. Company Name:
MNPR Stock Symbol:
NASDAQ Market:
Monopar Therapeutics Inc. Website:
WILMETTE, Ill., July 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the enrollment of the first patient in its first-in-human Phase 1 dosimetry and imaging...
WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled “Evaluation of Anti-uPAR Antibody as a Radiopharmaceuti...
Highlights: Builds on Companies’ respective core strengths Aligns intellectual property rights Establishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar’s development and potential future commercial programs WILMETTE, ...